J&J's Weldon to get $143M in retirement

William C. Weldon, who oversaw Johnson & Johnson ($JNJ) during some of its most troubled years, will receive $143.5 million in retirement and deferred compensation after he relinquishes the CEO position, Bloomberg reports. In the last few years, J&J has had a raft of manufacturing problems at McNeil Consumer Health that led to the closing of a plant and the recall of products such as Tylenol. It has faced recalls and litigation over is hip implant products and a scandal over the marketing of its schizophrenia drug Risperdal. Just this week, reports said the Department of Justice had turned down a $1.3 billion settlement offer from J&J for its Risperdal problems because it wasn't enough. Story
 

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.